Compare NEON & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | RNTX |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | Sweden | United States |
| Employees | 43 | 11 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 30.0M |
| IPO Year | 1994 | N/A |
| Metric | NEON | RNTX |
|---|---|---|
| Price | $1.65 | $1.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 96.7K | 82.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $1.02 |
| 52 Week High | $29.90 | $2.22 |
| Indicator | NEON | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 67.89 |
| Support Level | N/A | $1.34 |
| Resistance Level | $2.04 | $1.57 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 34.44 | 86.82 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.